EyePoint's Rollercoaster Week: A Glimmer of Hope Amidst Trial Setbacks and Downgrades Lam Research: Wall Street Delivers a 'Blunt Message' Post-Earnings Intellia's Big Chill: Manufacturing Woes Trigger a Wave of Downgrades MoonLake Therapeutics (MLTX) Shares Surge: A Deep Dive into Its Resilience Amidst Analyst Skepticism